Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies for diseases with unmet medical needs, announced today the results from three Phase I clinical trials of Bendavia, a novel compound that targets the mitochondrion to treat mitochondrial dysfunction, including ischemia reperfusion and microvascular injury. The studies evaluated the potential for interactions between Bendavia and several drugs routinely administered to patients undergoing inâ€“hospital interventional procedures. During the studies, volunteers received a single dose of Bendavia administered as an intravenous infusion followed by a standard dose of heparin, aspirin or clopidogrel.Â Results from these clinical trials indicate that Bendavia does not appear to affect the pharmacodynamics of these commonly used drugs. Safety data from these studies and preliminary results also demonstrate that Bendavia appears to be safe and wellâ€“tolerated at the doses evaluated, with no serious adverse events reported. Pharmacokinetic analysis from related clinical studies also showed highly predictable doseâ€“proportional exposure of Bendavia among volunteers.
The initial clinical program for Bendavia is the treatment of ischemia reperfusion injury, a common complication of interventional procedures for acute myocardial infarction (AMI) and coronary bypass surgery. Standard animal models for AMI demonstrate Bendaviaâ€™s beneficial myocardial effects and confirm the significance of its novel mechanism of action, which preserves mitochondrial function under pathological conditions for ischemia reperfusion and microvascular injury.
Contrary to prior therapeutic strategies for ischemia reperfusion injury and AMI that focused on uniâ€“targeted pathways, Bendavia and its mitochondrial directed actions address the more complicated, multifactorial nature of diseases. Specifically, Bendavia maintains electron transport efficiency, mitochondrial respiration and adenosine triphosphate levels and prevents mitochondrial swelling and depolarization. Bendavia also appears to be a strong ophthalmologic protectant in preclinical models and holds promise as a treatment for disorders such as diabetic retinopathy and macular degeneration.
Stealthâ€™s CEO, Travis Wilson, remarked â€śStealth is very pleased with the drug interaction data and tolerability of Bendavia from these Phase I clinical trials. Based on data from several studies showing Bendaviaâ€™s potential benefit for such common cardiovascular and metabolic diseases as heart failure and diabetic retinopathy, we feel that it is a unique and promising therapeutic candidate for cardioâ€“renal and ophthalmologic disorders.â€ť
Stealth is currently enrolling patients in a multinational Phase II clinical study with Bendavia focused on ischemia reperfusion and microvascular injuries for patients experiencing acute STâ€“segment elevation myocardial infarction (STEMI). Stealthâ€™s Phase II clinical trial is termed EMBRACEâ€“STEMIâ„˘ for theÂ Evaluation of the Myocardial effects of Bendavia for reducing Reperfusion injury in patients with Acute Coronary Events.
About Stealth Peptides
Stealth Peptides Inc. (Stealth) is a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs. Stealth has a rich and promising pipeline of preclinical and clinical compounds from a unique class of short peptides (500â€“700 Daltons each) that target mitochondria. Published, peerâ€“reviewed data for these compounds suggest significantÂ in vitroÂ andÂ in vivo efficacy for metabolic, ophthalmologic, neurologic and cardioâ€“renal related disorders. The intellectual property portfolio around these compounds is exceptionally robust with compositions, including Bendavia, protectable by patent until 2031.
More information regarding Stealth and Bendavia is available atÂ www.stealthpeptides.com.Business Wire
Last updated on: 09/04/2012